João Conde, PhD
João Conde is an Assistant Professor and Group Leader at NOVA Medical School of Universidade Nova de Lisboa, ToxOmics, CEDOC. He received his PhD in Biology, specialty in NanoBiotechnology from the NOVA University and Universidad de Zaragoza in 2014, under the FP7 European Consortium NanoScieE+ – NANOTRUCK for the development of multifunctional gold nanoparticles for gene silencing. After, he was a Marie Curie Fellow at the Massachusetts Institute of Technology, Harvard-MIT Division for Health Sciences and Technology and in School of Engineering and Materials Science, Queen Mary University of London. From 2017 to 2019 he was a Junior Investigator at Instituto de Medicina Molecular. In 2019, he won an ERC Starting Grant to build a genetic biobarcode to profile breast cancer heterogeneity. He is also co-founder of the biotech company TargTex, Targeted Therapeutics for Glioblastoma Multiforme.
The main aspects related to the recognition and diffusion of his early contributions are: 70 articles in journals of Cancer Therapy, Materials Science and Biomedicine (Nat. Materials, Nat. Nanotechnology, Nat. Communications, PNAS, Accounts of Chemical Research, Progress in Materials Science, ACS Nano, Advanced Materials, JACS, Angewandte Chemie, Advanced Functional Materials, Trends in Cancer, Trends in Biotech., Biomaterials, etc.), more than 30 articles are as 1st author and more than 30 articles as corresponding author and cited nearly 4700 times (h-index 36). Several of them have been selected as cover page of journals such as Nature Nanotechnology (Covid-19 Special issue), Adv. Functional Materials, JACS, Angewandte Chemie, ACS Sensors, Biomaterials Science, ACS Applied Bio Mat, Adv. Healthcare Materials, Analytical & Bioanalytical Chemistry and BioTechniques. Moreover, 6 international patents were submitted and approved, all with relevant developments in nanomaterials-based platforms for cancer therapy and diagnosis. He was also awarded with several international awards, including the Wellcome Image Awards 2017, the Nano-Micro Letters Researcher Award, and the National Cancer Institute Image award.
Conde Lab is focused on the application of multifunctional nano-and-biomaterials for cancer therapy and diagnosis, especially for tumour imaging and targeting, gene therapy/editing and drug delivery.
Barbara B. Mendes, PhD
Bárbara B. Mendes is a PhD in Tissue Engineering, Regenerative Medicine & Stem Cells, from University of Minho (Portugal) in collaboration with the University of Pennsylvania (USA). She is the first-author and co-author of 9 full length papers published in international scientific journals (plus 1 under revision), 3 book chapters, 8 oral communications and 19 poster presentations. In addition, she is inventor of 1 international patent. She has an h-index of 6 according to Google Scholar, and 5 for Scopus, and her work was cited more than 120 times.
For nearly five years, she has been researching and engineering intrinsically bioactive systems as mimics of the native extracellular matrix that find multiple research and clinical applications in regenerative medicine and tissue engineering field. She is conducting research work in a multidisciplinary ground, from biomaterials, drug delivery to gene therapy.
João Conniot, PhD
João Conniot has a Master in Pharmaceutical Sciences from the University of Lisbon (Faculty of Pharmacy). He obtained his PhD in Pharmacy in 2018, from the same University, under the supervision of Prof. Florindo from iMed.ULisboa, with a PhD scholarship from the Portuguese Foundation for Science and Technology. During his PhD studies João Conniot designed and optimized delivery systems for the co-entrapment of tumor-associated antigens and small nucleotide sequences as cancer nano-vaccines. After his PhD, João has focused on developing immune-oncology and immune-engineering approaches to improve the clinical outcomes of cancer immunotherapies. In the project GelGeneCircuit he is studying the immune cell profile within the tumor microenvironment with multicolor miRNA circuits to assess cancer therapeutic outcomes.
Diana Sousa, MSc
Diana Sousa graduated in Biochemistry and obtained a Master degree in Biochemistry for Health at NOVA School of Science and Technology of the NOVA University. She worked for three years as a research fellow in different labs in the fields of Medical and Health Sciences with emphasis on Immunology, Cell Biology, Glycobiology and Cancer Therapeutics and acquired experience in antibody development and characterization, cell line manipulation and immune cell isolation/differentiation, focusing on immunomodulatory processes. She is also interested in the development of anti-cancer targeted therapeutics and diagnosis tools using nanobiomaterials and is currently pursuing her PhD in Biomedicine at the Conde Lab working on the ERC project "Cancer heterogeneity and therapy profiling using bioresponsive nanohydrogels for the delivery of multicolor logic genetic circuits".